KMT2A and leukemia: Dinaciclib, which inhibits the CDK9 component of pTEFb, showed efficacy in preclinical models both in vitro and in vivo, inducing apoptotic cell death in MLL-r leukemia models and inhibition of MLL target genes (165, 238).